Form 4: BioMarin Pharmaceutical Inc. Executive Erin Burkhart Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 714 shares of common stock at $90 per share on August 13, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On August 13, 2024, Erin Burkhart, the GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 714 shares of the company's common stock.
- The sale was executed at a price of $90 per share.
- The transaction was conducted under a pre-existing 10b5-1 trading plan established on November 29, 2023.
- Following the transaction, Burkhart directly owns 14,449 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an insider stock sale under a pre-arranged plan, so it doesn't inherently convey positive or negative sentiment. It's a neutral disclosure.
Industry Context
This is a routine disclosure of an insider stock sale. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 11/29/2023 | Date of execution of the 10b5-1 plan. |
| 08/13/2024 | Date of the transaction (stock sale). |
| 08/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.